Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: Role of endothelin-1

Diabetes

Volumn 54, Issue 9, 2005, Pages 2638-2644

  Harris, Alex K ^a   Hutchinson, Jim R ^a   Sachidanandam, Kamakshi ^a   Johnson, Maribeth H ^b   Dorrance, Anne M ^b   Stepp, David W ^b   Fagan, Susan C ^a   Ergul, Adviye ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; GELATINASE A; GLUCOSE; INSULIN; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; EXTRACELLULAR MATRIX; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; RAT; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; BLOOD GLUCOSE; CEREBRAL ARTERIES; COLLAGEN; DIABETES MELLITUS, TYPE 2; ENDOTHELIN-1; GENE EXPRESSION REGULATION; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PHYSIOLOGIC; PYRROLIDINES; RATS; RECEPTOR, ENDOTHELIN A; TELENCEPHALON;

EID: 24144442641     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.9.2638     Document Type: Article

References (50)

1. American Diabetes Association: National diabetes fact sheet, 2002 [article online]. Available from http://www. diabetes.org/diabetes-statistics/ national-diabetes-fact-sheet.jsp
2. American Heart Association: Heart and stroke statistical update, 2002
3. Kernan WN, Inzucchi SE: Type 2 diabetes mellitus and insulin resistance: Stroke prevention and management. Curr Treat Options Neurol 6:443-450, 2004
4. Chakir M, Plante G: Endothelial dysfunction in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 54:45-51, 1996
5. Klein RL, Colwell JA: Altered endothelial function in diabetes mellitus. In Contemporary Endocrinology: Endocrinology of the Vasculature. Sowers JR, Ed. Totowa, NJ, Humana-Press, 1996
6. Evans T, Deng DX, Chen S, Chakrabarti S: Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 49:662-666, 2000
7. Gilbert RE, Rumble JR, Cao Z, Cox AJ, van Eeden P, Allen TJ, Kelly DJ, Cooper ME: Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res 86:158-165, 2000
8. Dumont AS, Dumont RJ, McNeill JH, Kassell NF, Sutherland GR, Verma S: Chronic endothelin antagonism restores cerebrovascular function in diabetes. Neurosurgery 52:653-660, 2003
9. Nagase H, Woessner JF: Matrix metalloproteinases. J Biol Chem 274: 21491-21494, 1999
10. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL: Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension 39:679-684, 2002
11. Ammarguellat F, Larouche II, Schiffrin EL: Myocardial flbrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation 103:319-324, 2001
12. Galis ZS, Sukhova G, Lark M, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2494-2503, 1994
13. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90:251-262, 2002
14. Williams JM, Pollock JS, Pollock DM: Arterial pressure response to the antioxidant tempol and ETB receptor blockade in rats on a high-salt diet. Hypertension 44:770-775, 2004
15. Ergul A, Portik-Dobos V, Giulumian AD, Molero MM, Fuchs LC: Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol 285:H2225-H2232, 2003
16. Pollock DM, Pollock JS: Evidence for endothelin involvement in the response to high salt. Am J Physiol 281:F144-F150, 2001
17. Conover W, Iman R: Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat 35:124-133, 1981
18. Cooper ME, Gilbert RE, Jerums G: Diabetic vascular complications. Clin Exp Pharmacol Physiol 24:770-775, 1997
19. Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G, Gilbert RE: Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest 99:1016-1027, 1997
20. Cooper ME, Rumble J, Komers R, Du HC, Jandeleit K, Chou ST: Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 43:1221-1228, 1994
21. Intengan HD, Schiffrin EL: Structure and mechanical properties of resistance arteries in hypertension. Hypertension 36:312-318, 2000
22. Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, Vapaatalo H, Muller D, Park J-K, Luft FC, Mervaala EMA: Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 37:433-439, 2001
23. Ostenson CG: The Goto-Kakizaki rat. In Animal Models of Diabetes: A Primer. Sima A, Shafrir E, Eds. Amsterdam, Harwood Academic Publishers, 2001
24. Seica RM, Suzuki KI, Santos RM, Do Rosario LM: [Impaired insulin secretion in isolated islets of Goto-Kakizaki rats, an animal model of non obese type 2 diabetes, is a primary event] Acta Med Port 17:42-48, 2004 [article in Portuguese]
25. Seica RM, Martins MJ, Pessa PB, Santos RM, Rosario LM, Suzuki KI, Martins MI: [Morphological changes of islet of Langerhans in an animal model of type 2 diabetes.] Acta Med Port 16:381-388, 2003 [article in Portuguese]
26. Kitahara Y, Miura K, Takesue K, Mine T, Wada R, Uchida Y, Ito S, Yagihashi S: Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes. Metabolism 51:1452-1457, 2002
27. Ladriere L, Bjorkling F, Malaisse WJ: Stimulation of insulin release in hereditarily diabetic rats by mixed molecules formed of nateglinide and a succinic acid ester. Int J Mol Med 5:63-65, 2000
28. Metz SA, Meredith M, Vadakekalam J, Rabaglia ME, Kowluru A: A defect late in stimulus-secretion coupling impairs insulin secretion in Goto-Kakizaki diabetic rats. Diabetes 48:1754-1762, 1999
29. Iida KT, Kawakami Y, Suzuki M, Shimano H, Toyoshima H, Sone H, Shimada K, Iwama Y, Watanabe Y, Mokuno H, Kamata K, Yamada N: Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol 284:E1125-E1130, 2003
30. Schram MT, Henry RMA, van Dijk RAJM, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Westerhof N, Stehouwer CDA: Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 43:176-181, 2004
31. Haak T, Jungmann E, Felber A, Hillmann U, Usadel KH: Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens 5:161-166, 1992
32. Collier A, Leach JP, McLellan A, Jardine A, Morton JJ, Small M: Plasma endothelin-like immunoreactivity levels in IDDM patients with microalbuminuria. Diabetes Care 15:1038-1040, 1992
33. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR: Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33:306-310, 1990
34. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah N, Touyz B, Reudelhuber T, Schiffrin EL: Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110:2233-2240, 2004
35. Tostes RC, Touyz RM, He G, Ammarguellat F, Schiffrin EL: Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 39:892-900, 2002
36. Ishikawa Y, Asuwa N, Ishii T, Ito K, Akasaka Y, Masuda T, Zhang L, Kiguchi H: Collagen alteration in vascular remodeling by hemodynamic factors. Virchows Arch 437:138-148, 2000
37. Johnson JL, van Eys GJ, Angelini GD, George SJ: Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein. Arterioscler Thromb Vasc Biol 21:1146-1151, 2001
38. George SJ: Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Investig Drugs 9:993-1007, 2000
39. Johnson JL, Jackson CL, Angelini GD, George SJ: Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 18:1707-1715, 1998
40. Shah BH, Catt KJ: A central role of EGF receptor transactivation in angiotensin II-induced cardiac hypertrophy. Trends Pharmacol Sci 24: 239-244, 2003
41. Saito S, Frank GD, Motley ED, Dempsey PJ, Utsunomiya H, Inagami T, Eguchi S: Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem Biophys Res Commun 294:1023-1029, 2002
42. Konishi A, Berk BC: Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J Biol Chem 278:35049-35056, 2003
43. Flamant M, Tharaux PL, Placier S, Henrion D, Coffman T, Chatziantoniou C, Dussaule JC: Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 17:327-329, 2003
44. Saito Y, Berk BC: Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol 33:3-7, 2001
45. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ: Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 26:2120-2126, 1995
46. Rosenberg GA, Navratil M, Barone F, Feuerstein G: Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 16:360-366, 1996
47. Chang DI, Hosomi N, Lucero J, Heo JH, Abumiya T, Mazar AP, del Zoppo GJ: Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab 23:1408-1419, 2003
48. Magnoni S, Baker A, George SJ, Duncan WC, Kerr LE, McCulloch J, Horsburgh K: Differential alterations in the expression and activity of matrix metalloproteinases 2 and 9 after transient cerebral ischemia in mice. Neurobiol Dis 17:188-197, 2004
49. Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston LL Jr, del Zoppo GJ: Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 35:998-1004, 2004
50. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH: Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood flow Metab 20:1681-1689, 2000